Innophos Holdings, Inc. provided earnings guidance for the fourth quarter and reiterates earnings guidance for the full year of 2018. The company is revising its full year 2018 revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance with revenue expected to grow 10% to 12% (previously was 12% to 14%) compared with full year 2017 revenue of $722 million. Adjusted EBITDA is expected to grow 3% to 7% (previously was 15% to 17%) compared with adjusted EBITDA of $120 million for full year 2017. The revised revenue guidance reflects lower-than-expected nutrition sales in the second half of 2018, principally driven by the company's decision to discontinue a portion of lower-margin trading business ahead of plan. To better position for future revenue and earnings growth, the company continues to actively transition the lower-margin ingredients portion of its acquired portfolio to more value-adding solutions. Further, the company has taken steps to protect its 2018 free cash flow delivery and is announcing its intention to finalize a sale lease-back transaction during fourth quarter on a non-core asset for an estimated $20 million in cash. This transaction, along with the previously communicated $20 million Nutrien payment, is expected to generate an estimated $40 million in positive cash flow in the fourth quarter of 2018.